You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

471 Results
Il vous est demandé, au travers des questions posées dans l’enquête Votre opinion est importante, d’exprimer votre ressenti quant à votre plus récent...
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Blinatumomab - Minimal Residual Disease (MRD)-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
blinatumomab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Document
Nov 2021
Document
Nov 2021
Document
Nov 2021
Document
Nov 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - T-cell, 
Rare Diseases
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - Previously Treated Primary Cutaneous Anaplastic Large Cell Lymphoma or Mycosis Fungoides
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
brentuximab vedotin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Pegaspargase - Extranodal Natural Killer/T-cell Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
methotrexate,
leucovorin,
ifosfamide,
mesna,
dexamethasone,
etoposide,
pegaspargase
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
sotorasib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2022
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    binimetinib - For the treatment of patients with locally advanced unresectable or metastatic melanoma with a BRAF V600 mutation, according to clinical criteria.
Exceptional Access Program
    encorafenib - For the treatment of patients with locally advanced unresectable or metastatic melanoma with a BRAF V600 mutation, according to clinical criteria.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
binimetinib,
encorafenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024

Pages